Cytomos is presenting its AuraCyt platform at BIO 2026, showcasing a digital cell analytics system designed to improve speed and predictability in bioprocessing decision-making.

Cytomos is demonstrating its AuraCyt platform and Celledonia benchtop analyser at the BIO International Convention in San Diego, positioning the technology as a tool to enable earlier and more predictive decision-making in bioprocess development.

The company said the system addresses long-standing challenges in biomanufacturing, where traditional label-dependent analytical methods are often slow, difficult to scale and limited in predictive value.

Cytomos said its platform “captures a digital fingerprint of every cell,” enabling label-free, single-cell analysis designed to generate high-resolution insights into cell health, phenotype and function.

The company added that the approach is intended to deliver “rapid, label-free, single-cell analysis” capable of predicting future productivity, stability and manufacturability, supporting earlier-stage decision-making in bioprocess workflows.

The Celledonia system integrates silicon sensor technology with Cytomos’ AuraCyt analysis suite to translate cellular data into predictive outputs intended to support process optimisation and product consistency.

According to the company, the system may reduce cell line development timelines by up to 40%, lower resource use in lentiviral production by up to 65%, and shorten CAR-T manufacturing processes by up to 30%, although these figures are based on internal modelling and deployment scenarios.

Executive chair Alan Raymond said customers and partners can be “confident that Cytomos operates to the highest international standards,” following the company’s recent ISO 9001 certification with zero non-conformances.

He added that the certification is “not just a badge,” but reflects the company’s aim to deliver “reliable, reproducible, and meaningful results in cell analysis.”

Raymond described the AuraCyt system as a step change in bioprocess insight, stating that it enables users to “see what’s coming — before it happens,” by detecting cellular features that currently lack established biomarkers.

The company is engaging with industry partners to integrate the platform into existing bioprocessing workflows, supported by dedicated scientific and data teams working across development and manufacturing applications.

Cytomos is exhibiting at BIO 2026 in the UK Pavilion, where it is presenting the platform to potential partners across drug discovery, development and manufacturing sectors.